



Page 1 of 16

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	<i>ATTACH TO 8/13/02</i>
		FILING DATE January 23, 2002	GROUP 1642


U. S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AE						
	AT						
	AM						
	AF						
	AC						
	AB						
	AI						
	AN						
	AF						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
LO	AL1	EP 0 531 300 B1	03/17/1993	Europe	—	—	Yes No
LP	AM1	EP 0 538 754 A2	04/28/1993	Europe	—	—	Yes No
LP	AM1	WD 94/02633 A1	02/03/1994	WIPO	—	—	Yes No
LP	AO1	WD 94/12631 A1	06/09/1994	WIPO	—	—	Yes No
WA	AP1	WD 95/00851 A1	01/05/1995	WIPO	—	—	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
LO	AE	1	Breitz, H.B., et al., "Clinical Experience with Rhenium-186-Labeled Monoclonal Antibodies for Radioimmunotherapy: Results of Phase I Trials," <i>J. Nucl. Med.</i> 33:1099-1109, The Society of Nuclear Medicine (1992)				
LP	AS	1	Breitz, H.B., et al., "Pharmacokinetics and Normal Organ Dosimetry Following Intraperitoneal Rhenium-186-Labeled Monoclonal Antibody," <i>J. Nucl. Med.</i> 36:754-761, The Society of Nuclear Medicine (May 1995)				
LP	AT	1	Chatterjee, M.B. et al., "Idiotypic antibody immunotherapy of cancer," <i>Cancer Immunol. Immunother.</i> 38:75-82, Springer-Verlag (1994)				

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED <i>2/2/04</i>
------------------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AJ							
AK							
AL							
AM							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED  
 AUG 15 2002  
 TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AM	AI2	WO 96/00658 A1	01/05/1995	WIPO			Yes No
	AM						Yes No
	AM						Yes No
	AM						Yes No
	AM						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

20	AF	2	Chaudhary V.K. et al., "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," Proc. Natl. Acad. Sci. USA 87:1066-1070, National Academy Press (1990)
21	AS	2	Ermak, G., et al., "Restricted Patterns of CD44 Variant Exon Expression in Human Papillary Thyroid Carcinoma," Cancer Res. 56:1037-1042, American Association for Cancer Research (March 1996)
22	AT	2	Fox, S.B., et al., "CD44 and cancer screening," Lancet 342:546-549, Williams & Wilkens (1993)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	2/2/02
----------	--------------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 3 of 15

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652-1510001/EFS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIJER et al.	
		FILING DATE January 23, 2002	GROUP 1042

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AJ							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							
AO							
AP							
AQ							
AR							
AS							
AT							
AV							
AW							
AX							
AY							
AZ							

RECEIVED  
AUG 13 2002  
TECH CENTER 123200

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AA							Yes No
AB							Yes No
AC							Yes No
AD							Yes No
AE							Yes No
AF							Yes No
AG							Yes No
AH							Yes No
AI							Yes No
AJ							Yes No
AK							Yes No
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No
AG							Yes No
AS							Yes No
AT							Yes No
AV							Yes No
AW							Yes No
AX							Yes No
AY							Yes No
AZ							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>Heijer</i>	AF	3	Fox, S.B., et al., "Normal Human Tissues, in Addition to Some Tumors, Express Multiple Different CD44 Isoforms," <i>Cancer Res.</i> 54:4539-4546, American Association for Cancer Research (1994)
<i>M</i>	AS	3	Friedrichs, K., et al., "CD44 Isoforms Correlate with Cellular Differentiation but not with Prognosis in Human Breast Cancer," <i>Cancer Res.</i> 55:5424-5433, American Association for Cancer Research (November 1995)
<i>W</i>	AT	3	Fujiwara, K., et al., "Expression of a Lymphocyte Adhesion Molecule (CD44) in Malignant Lymphomas: Relevance to Primary Site, Histological Subtype and Clinical Stage," <i>Acta Med. Okayama</i> 47:215-222, Okayama University Medical School (1993)

EXAMINER

DATE CONSIDERED

*2/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 4 of 15

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
A1							
A2							
A3							
A4							
A5							
A6							
A7							
A8							
A9							
A10							
A11							
A12							
A13							
A14							
A15							
A16							
A17							
A18							
A19							
A20							
A21							
A22							
A23							
A24							
A25							
A26							
A27							
A28							
A29							
A30							
A31							
A32							
A33							
A34							
A35							
A36							
A37							
A38							
A39							
A40							
A41							
A42							
A43							
A44							
A45							
A46							
A47							
A48							
A49							
A50							
A51							
A52							
A53							
A54							
A55							
A56							
A57							
A58							
A59							
A60							
A61							
A62							
A63							
A64							
A65							
A66							
A67							
A68							
A69							
A70							
A71							
A72							
A73							
A74							
A75							
A76							
A77							
A78							
A79							
A80							
A81							
A82							
A83							
A84							
A85							
A86							
A87							
A88							
A89							
A90							
A91							
A92							
A93							
A94							
A95							
A96							
A97							
A98							
A99							
A100							
A101							
A102							
A103							
A104							
A105							
A106							
A107							
A108							
A109							
A110							
A111							
A112							
A113							
A114							
A115							
A116							
A117							
A118							
A119							
A120							
A121							
A122							
A123							
A124							
A125							
A126							
A127							
A128							
A129							
A130							
A131							
A132							
A133							
A134							
A135							
A136							
A137							
A138							
A139							
A140							
A141							
A142							
A143							
A144							
A145							
A146							
A147							
A148							
A149							
A150							
A151							
A152							
A153							
A154							
A155							
A156							
A157							
A158							
A159							
A160							
A161							
A162							
A163							
A164							
A165							
A166							
A167							
A168							
A169							
A170							
A171							
A172							
A173							
A174							
A175							
A176							
A177							
A178							
A179							
A180							
A181							
A182							
A183							
A184							
A185							
A186							
A187							
A188							
A189							
A190							
A191							
A192							
A193							
A194							
A195							
A196							
A197							
A198							
A199							
A200							
A201							
A202							
A203							
A204							
A205							
A206							
A207							
A208							
A209							
A210							
A211							
A212							
A213							
A214							
A215							
A216							
A217							
A218							
A219							
A220							
A221							
A222							
A223							
A224							
A225							
A226							
A227							
A228							
A229							
A230							
A231							
A232							
A233							
A234							
A235							
A236							
A237							
A238							
A239							
A240							
A241							
A242							
A243							
A244							
A245							
A246							
A247							
A248							
A249							
A250							
A251							
A252							
A253							
A254							
A255							
A256							
A257							
A258							
A259							
A260							
A261							
A262							
A263							
A264							
A265							
A266							
A267							
A268							
A269							
A270							
A271				</			



Page 5 of 16

FCRM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AS							
AH							
AJ							
AK							

RECEIVED  
FEBR 15 2002  
FEDERAL CENTER 16022900

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AV							Yes No
AN							Yes No
AD							Yes No
AS							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>MM</i>	AE	5	Heider, K.-H., et al., "A Human Homologue of the Rat Metastasis-associated Variant of CD44 Is Expressed in Colorectal Carcinomas and Adenomatous Polyps," <i>J. Cell Biol.</i> 120:227-233, The Rockefeller University Press (1993)
<i>LA</i>	AS	5	Heider, K.-H., et al., "Expression of CD44 isoforms in human renal cell carcinomas," <i>Virchows Arch.</i> 428:267-273, Springer-Verlag (July 1996)
<i>HP</i>	AT	5	Hofmann, M., et al., "CD44 Splice Variants Confer Metastatic Behavior in Rats: Homologous Sequences Are Expressed in Human Tumor Cell Lines," <i>Cancer Res.</i> 51:5292-5297, American Association for Cancer Research (1991)

EXAMINER *[Signature]* DATE CONSIDERED *2/2/02*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 6 of 16

FORM PTC-1449  <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0652.19100C1/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

**RECEIVED**  
AUG 13 2002  
TECH CENTER 1600  
2002

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>Horst</i>	AR	6	Horst, E., et al., "Expression of a Human Homing Receptor (CD44) in Lymphoid Malignancies and Related Stages of Lymphoid Development," Leukemia 4:383-393, Williams & Wilkins (1990)
<i>Horst</i>	AS	6	Horst, E., et al., "Adhesion Molecules in the Prognosis of Diffuse Large-Cell Lymphoma: Expression of a Lymphocyte Homing Receptor (CD44), LFA-1 (CD11a, 1b), and ICAM-1 (CD54)," Leukemia 4:595-599, Williams & Wilkins (1990)
<i>Jackson</i>	AT	6	Jackson, D.G., et al., "Multiple Variants of the Human Lymphocyte Homing Receptor CD44 Generated by Insertions at a Single Site in the Extracellular Domain," J. Biol. Chem. 267:4732-4739, The American Society for Biochemistry and Molecular Biology, Inc. (1992)

EXAMINER

DATE CONSIDERED

*2/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 7 of 16

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED  
AUG 13 2002  
TECH CENTER RECEIVED

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AIJ							Yes No
AM1							Yes No
AM2							Yes No
AN1							Yes No
AN2							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>H</i>	AF	7	Jain, R.K., "Barriers to Drug Delivery in Solid Tumors," <i>Sci. Am.</i> 271:58-65, Scientific American, Inc. (1994)
<i>V</i>	AS	7	Jalkanen, S., et al., "Lymphocyte Homing and Clinical Behavior of Non-Hodgkin's Lymphoma," <i>J. Clin. Invest.</i> 87:1835-1840, The American Society for Clinical Investigation, Inc. (1991)
<i>W</i>	AT	7	Juveid, M., et al., "Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, an Anti-CD22 Monoclonal Antibody," <i>Cancer Res. (Suppl.)</i> 55:5899s-5907s, American Association for Cancer Research (December 1995)

EXAMINER

DATE CONSIDERED

*2/2/04*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 604. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



AUG 13 2002

Page 3 of 16

 <b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>	<b>ATTY. DOCKET NO.</b> <b>0652.1910001/EKS/PSC</b>	<b>APPLICATION NO.</b> <b>10/052,641</b>
	<b>APPLICANT</b> <b>HEIDER et al.</b>	
	<b>FILING DATE</b> <b>January 24, 2002</b>	<b>GROUP</b> <b>1642</b>

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
A3							
A3							
A1							
A7							
A3							
A7							
A1							
AH							
A1							
A1							
A3							

RECEIVED  
AUG 15 2009  
TECH CENTER 1800/6500

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	A1						Yes No
	A2						Yes No
	A3						Yes No
	A4						Yes No
	A5						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>b</i>	AF	<i>E</i>	Kaufmann, M., et al., "CD44 variant exon epitopes in primary breast cancer and length of survival," <i>Lancet</i> 341:615-619, The Lancet, Ltd. (March 1995)
<i>v/a</i>	AS	<i>E</i>	Koopman, G., et al., "Activated Human Lymphocytes and Aggressive Non-Hodgkin's Lymphomas Express a Homologue of the Rat Metastasis-associated Variant of CD44," <i>J. Exp. Med.</i> 177:897-904, The Rockefeller University Press (1993)
<i>w</i>	AT	<i>E</i>	Mackay, C.R. et al., "Expression and Modulation of CD44 Variant Isoforms in Humans," <i>J. Cell. Biol.</i> 124:71-82, The Rockefeller University Press (1994)

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 9 of 12

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AJ							
AK							
AL							
AM							
AN							
AO							
AP							
AS							
AT							
AV							
AW							

**RECEIVED**  
AUG 15 2002  
TECH CENTER 1600/290

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AM							Yes No
AN							Yes No
AS							Yes No
AT							Yes No
AV							Yes No
AW							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AF	g	Möller, P., et al., "Venular endothelium binding molecules CD44 and LECA4-1 in normal and malignant B-cell populations. A comparative study," <i>Virchows Arch. A. Pathol. Anat.</i> 421:305-313, Springer-Verlag (1992)
	AS	g	Mulder, J.-W.R., et al., "Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins," <i>Lancet</i> 344:1470-1472, The Lancet, Ltd. (1994)
	AT	g	Pals, S.T., et al., "Expression of Lymphocyte Homing Receptor as a Mechanism of Dissemination in Non-Hodgkin's Lymphoma," <i>Blood</i> 73:885-888, Grune & Stratton (1989)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 09. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 10 of 15

INFORMATION DISCLOSURE STATEMENT FORM PTO-1449	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AJ							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AZ							
AJ							
AZ							

*RECEIVED*  
AUG 15 2002  
TEST CENTER 16012920

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AB							Yes No
AI							Yes No
AM							Yes No
AO							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>[Signature]</i>	AF	10	Picker, L.J., et al., "Expression of Lymphocyte Homing Receptor Antigen in Non-Hodgkin's Lymphoma," Am. J. Pathol. 130:496-504, American Association of Pathologists (1988)
<i>[Signature]</i>	AS	10	Press, G. W., et al., "Phase II trial of <sup>131</sup> I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas," Lancet 346:336-340, The Lancet, Ltd. (August 1995)
<i>[Signature]</i>	AT	10	Quadri, S.M., et al., "Evaluation of Indium-111- and Yttrium-90-Labeled Linker-Immunoconjugates in Nude Mice and Dogs," J. Nucl. Med. 34:938-945, The Society of Nuclear Medicine, Inc. (1993)

EXAMINER

DATE CONSIDERED

*2/2/01*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 11 of 15

INFORMATION DISCLOSURE STATEMENT FORM PTO-1449	ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 16/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED  
AUG 15 2002  
TECH CENTER 1642

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AI							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>HO</i>	AR	<u>11</u>	Ristamäki, R., et al., "Serum CD44 in Malignant Lymphoma: An Association With Treatment Response," <i>Blood</i> 84:238-243, W.B. Saunders Company (1994)
<i>WA</i>	AS	<u>11</u>	Eistamäki, R., et al., "CD44v6 Expression in Non-Hodgkin's Lymphoma: an Association with Low Histological Grade and Poor Prognosis," <i>J. Pathol.</i> 175:259-267, John Wiley & Sons, Ltd. (July 1995)
<i>WT</i>	AT	<u>11</u>	Salles, G., et al., "Alternatively Spliced CD44 Transcripts in Diffuse Large-Cell Lymphomas: Characterization and Comparison With Normal Activated B Cells and Epithelial Malignancies," <i>Blood</i> 82:3539-3547, W.B. Saunders Company (1993)

EXAMINER:

DATE CONSIDERED

*2/2/02*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 12 of 16

FORM PTC-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GRCPUP 1642

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AJ							
AB							
AT							
AD							
AE							
AF							
AV							
AH							
AI							
AS							
AR							

RECEIVED  
AUG 15 2002  
EFT CENTER 160280


**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
AI							Yes No
AT							Yes No
AD							Yes No
AV							Yes No
AS							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>AS</i>	AF	12	Savage, P., et al., "A recombinant single chain antibody interleukin-2 fusion protein," Br. J. Cancer 67:304-310, Macmillan Press, Ltd. (1993)
<i>AS</i>	AS	12	Screaton, G.R., et al., "Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons," Proc. Natl. Acad. Sci. USA 90:12160-12164, National Academy Press (1992)
<i>AS</i>	AT	12	Screaton, G.R., et al., "The Identification of a New Alternative Exon with Highly Restricted Tissue Expression in Transcripts Encoding the Mouse Pgp-1 (CD44) Homing Receptor," J. Biol. Chem. 268:12235-12238, The American Society for Biochemistry and Molecular Biology, Inc. (1993)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0651.1910001/EKS/PSC	APPLICATION NO. 10/052,641
	APPLICANT HEIDER et al.	
	FILING DATE January 23, 2002	GFOUP 1642

## U.S. PATENT DOCUMENTS

EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED  
AUG 15 2002

TECH CENTER 1600/2530

## FOREIGN PATENT DOCUMENTS

EXAMINEE INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AT							Yes No
AF							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AF	<u>12</u>	Seaver, S., "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought," Genet. Eng. News 14:10,21, Mary Ann Liebert, Inc. (1994)
	AS	<u>12</u>	Seiter, S., et al., "Prevention of Tumor Metastasis Formation by Anti-Variant CD14," J. Exp. Med. 177:443-455, The Rockefeller University Press (1993)
	AT	<u>12</u>	Stamenkovic, I., et al., "A Lymphocyte Molecule Implicated in Lymph Node Homing Is a Member of the Cartilage Link Protein Family," Cell 56:1057-1062, Cell Press (1989)

EXAMINER		DATE CONSIDERED
----------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							

RECEIVED  
AUG 15 2002  
TECH CENTER 1600/2000

## FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AI							Yes No
AJ							Yes No
AJ							Yes No
AO							Yes No
AI							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>LA</i>	AR	14	Stauder, R., et al., "CD44 Variant Isoforms in Non-Hodgkin's Lymphoma: A New Independent Prognostic Factor," <i>Blood</i> 85:2885-2899, W.B. Saunders Company (May 1995)
<i>MW</i>	AS	14	Tanabe, K.K., et al., "Expression of CD44R1 adhesion molecule in colon carcinomas and metastases," <i>Lancet</i> 341:725-726, Williams & Wilkins (1993)
<i>WT</i>	AT	14	Terpe, H.-J., et al., "CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues," <i>Histochemistry</i> 101:79-89, Springer-Verlag (1994)

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>26/04</i>
----------	--------------------	-----------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 15 of 16

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652-1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							

RECEIVED  
AUG 15 2002  
TECH CENTER 1600/200

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AM2							Yes No
AM							Yes No
AM							Yes No
AM							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

24	AR	15	Thomas, G.D., et al., "Antibodies for tumour immunodetecting and methods for antibody radiolabelling," in <i>Antibodies. Volume II. A Practical Approach</i> , Volume II, Catty, D., ed., IRL Press, Oxford, UK, pp. 223-244 (1989)
W	AS	15	Tölg, C., et al., "Splicing choice from ten variant exons establishes CD44 variability," <i>Nucl. Acids Res.</i> 21:1225-1229, Oxford University Press (1993)
W	AT	15	Vriesendorp, H.M. et al., "Review of Five Consecutive Studies of Radiolabeled Immunoglobulin Therapy in Hodgkin's Disease," <i>Cancer Res. (Suppl.)</i> 55:5888s-5892s, American Association for Cancer Research (December 1995)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 16 of 16

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 0652.1910001/EKS/PSC	APPLICATION NO. 10/052,641
		APPLICANT HEIDER et al.	
		FILING DATE January 23, 2002	GROUP 1642

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

**RECEIVED**  
AUG 15 2002  
TECH CENTER 1600  
EFS/PSC

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>LL</i>	AR	16	Dialog File 351, Accession No. 91-340908/199147, Derwent WPI English language abstract for EP 0 531 300 B1 (Document AL1)
<i>AS</i>	AS	15	Dialog File 351, Accession No. 93-136002/199317, Derwent WPI English language abstract for EP 0 538 754 A1 (Document AM1)
<i>WV</i>	AT	16	Dialog File 351, Accession No. 95-052230/199507, Derwent WPI English language abstract for WO 95/00851 (Document AP1)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.